

In Vitro Diagnostics Market 2008-2023

3 The World In Vitro Diagnostics Market 2013-2023

3.1 Significant Sales Growth Predicted for the Overall Global In Vitro Diagnostics Market from 2007 to 2023

Molecular IVD technologies are playing a central role in the pharmacogenomics revolution. Those developments will become increasingly prominent in healthcare during the period 2008-2023, raising the profile of the diagnostics industry considerably. Visiongain foresees closer links between the healthcare industries, especially between diagnostics and pharmaceuticals.

3.1.1 IVD Market Led by Metabolism, Oncology and Infection Market Segments

Visiongain predicts that the world market for in vitro diagnostics (IVD) will expand from \$xx bn 20xx to \$xx bn in 20xx, then to \$xx bn in 20xx. By 20xx, the market will have reached \$xx bn. That growth of sales will represent a CAGR of xx% between 20xx and 20xx. Table 3.1, Table 3.2, Table 3.3 and Table 3.4 show visiongain's forecast of the overall in vitro diagnostics market and its principal sub-components from 20xx to 20xx, with CAGR values. That information is shown graphically in Figure 3.2 and Figure 3.4.

All the values quoted in this chapter are for IVD products and services related to human healthcare, including test kits and specialised molecular applications, including dedicated instrumentation (e.g., relevant PCR applications). Consequently, the market is diverse and hard to delineate, especially since the technology frequently overlaps with other fields, such as veterinary medicine, food testing, biodiversity testing and biological sciences.

Within the overall in vitro diagnostics market, the fastest growing therapeutic area segments will be metabolism and oncology. Sales in those areas and others will be increasingly reliant on biotechnological assays such as nucleic acid testing and monoclonal antibodies (immunodiagnostics), with an increasing emphasis on nucleic acid testing during the years ahead. The revenues for those areas will increase from \$xx bn 20xx to \$xx bn in 20xx; by 20xx the metabolism segment will have reached \$xx bn and the oncology segment \$xx bn, with CAGR values of xx% and xx% respectively. Table 3.1, Table 3.2, Table 3.3,

In Vitro Diagnostics Market 2008-2023

7 Theranostics Market Analysis, 2007-2023

7.1 Theranostic Products Will Constitute a Major Driver of the Global IVD Market

7.1.1 IVD Theranostics Market to Expand to Multi-Billion Dollar Sales by 2013

The much-heralded era of personalised medicine will depend on drugs eventually having a companion theranostic - a test specifically designed to predict whether a patient will benefit from the treatment or to monitor how well it is working. Visiongain predicts that by some time next decade most branded drugs will have specific diagnostic tests associated with them, especially for determining the patients who can benefit most from the drugs and who those who can tolerate higher doses.

Visiongain predicts that the overall world market for theranostic agents (companion diagnostics) will expand from \$xx bn 20xx to \$xx bn in 20xx, then to \$xx bn in 20xx. By 20xx, the theranostics market will have reached \$xx bn. That growth of sales will represent a CAGR of xx % between 2007 and 2023. Table 7.1, Table 7.2, Table 7.3 show visiongain's forecast of the overall theranostics market and its principal therapeutic areas from 2007 to 2023, with CAGR values. That information is shown graphically in Figure 7.1, Figure 7.2, Figure 7.3, Figure 7.4, Figure 7.5 and Figure 7.6.

Table 7.4 summarises the longer range forecasts for those segments and the overall world theranostics market, with sales values and CAGR extended until 2023. All the values quoted in this chapter are for theranostic IVD products and services, excluding hardware and the accompanying drugs. Table 7.5 shows how the share of total world IVD sales contributed by theranostic applications will increase from xx % in 20xx to xx % in 20xx. Figure 7.7 and Figure 7.8 show that information graphically.